Pluristem prices $32m offering to progress stem cell therapies
This article was originally published in Clinica
Executive Summary
Allogeneic stem cell therapy developer Pluristem Therapeutics has priced a stock offering to raise gross proceeds of $32 million which will go towards financing research and development, including clinical trials of its cell-based vascular disease treatment. The company will offer eight million units – each unit consisting of one share of common stock and a warrant to purchase 35% of one share - at $4 per unit.